Dr. Irene Karungi's team at Imperial College London has found something that could reshape how doctors prevent heart disease: catching cholesterol problems years earlier, before damage silently accumulates in your arteries. The discovery comes from analyzing 17 clinical trials involving over 100,000 people, mostly with no prior heart disease or stroke, and the numbers suggest a fundamental shift in prevention strategy is long overdue.
The current approach waits. Under UK National Institute for Health and Care Excellence guidelines, doctors calculate a patient's 10-year risk of a heart attack or stroke and typically only prescribe cholesterol-lowering statins to those deemed "high-risk." Patients at lower risk—those with less than a 10% chance of a cardiac event in the next decade—often don't get treatment, because the math seems poor: too many people would need medication to prevent a single event. But this calculus misses a crucial reality: while you're waiting to become "high-risk," atherosclerosis is quietly building. Cholesterol deposits in artery walls, forming plaques that can remain stable for years until fragments break off and trigger clotting, blocking blood flow to the heart or brain.
The Imperial College research, presented at the European Atherosclerosis Society Congress in Athens and published in the American Journal of Preventive Cardiology, reveals the arithmetic changes dramatically when intervention happens earlier. In lower-risk patients treated at an early stage, reducing LDL cholesterol by just 0.36 mmol/liter yields a 25% reduction in major adverse cardiovascular events—heart attacks, strokes, and related emergencies. The British Heart Foundation recommends an LDL concentration under 3 mmol/liter; this finding suggests you don't need to slash that target dramatically to gain real benefit. But wait until atherosclerosis has progressed further, and the story inverts: high-risk patients need LDL reductions of more than 3 mmol/liter—nearly eight times larger—to achieve that same 25% risk reduction. That magnitude of change often demands higher doses of statins, which some patients cannot tolerate.
Across the 17 trials analyzed, there were 6,076 major adverse cardiovascular events. The pattern was unambiguous: the earlier you intervene, the smaller the chemical change required to protect against disease. It's a principle with profound implications. An estimated 8 million people in the UK currently have heart disease, a number projected to reach 10 million by 2040 as the population ages. Most of those 8 million were once at "lower risk"—a category where preventive treatment is still frequently deferred.
Karungi's statement captured the scope of what's at stake: "Current practice relies on 10-year risk to determine when to initiate treatment but this delays therapy until atherosclerosis is often already established." The finding suggests that shifting toward earlier detection and gentler intervention—smaller doses of existing drugs, or alternative medications for those who can't tolerate statins—could prevent disease before it takes root. It's a different philosophy entirely from waiting for risk scores to climb. For millions of people managing their cholesterol in coming years, that difference could mean the absence of a heart attack that would have otherwise arrived.